Skip to content

Rational use of NOACs in the real world and assessment of influencing factors: A multicenter retrospective study

Rational use of NOACs in the real world and assessment of influencing factors: A multicenter retrospective study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200055973
Enrollment
Unknown
Registered
2022-01-30
Start date
2022-02-01
Completion date
Unknown
Last updated
2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial fibrillation

Interventions

Patients who used NOACs:none

Sponsors

Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Continuous inclusion in the Shanghai area from Jan.1st, 2010 to Dec. 31st, 2021; 2. Diagnosis includes: heart rate, radiofrequency, atrial flutter, atrial fibrillation, heart thrombosis, deep venous thrombosis, pulmonary embolism, lower extremity venous thrombosis; 3. Aged 18 years and over, initial or already receiving warfarin. Prescriptions or doctor's advice for patients who receive rivaroxaban, apixaban, edoxaban, and dabigatran ester anticoagulant therapy.

Exclusion criteria

Exclusion criteria: 1. Prescriptions or doctor's orders that use oral anticoagulants for less than 1 day; 2. Prescriptions or orders of patients whose age, sex and other basic information are incomplete and can not be filled.

Design outcomes

Primary

MeasureTime frame
Percentage of unsuitable prescriptions / orders;

Secondary

MeasureTime frame
Factors influencing the rationality of anticoagulant therapy;

Countries

China

Contacts

Public ContactGu Zhichun

Department of Pharmacy, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine

guzhichun@renji.com+86 13917839479

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026